Similar Articles
671 Non-invasive tests for the prediction of primary hepatocellular carcinoma
672 Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
673 Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma
674 Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment
675 Pearls and pitfalls in magnetic resonance imaging of hepatocellular carcinoma
676 Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations
677 Pathological characterization of occult hepatitis B virus infection in hepatitis C virus-associated or non-alcoholic steatohepatitis-related hepatocellular carcinoma
678 Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors
679 Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?
680 Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA